BioDirection®, Inc. Closes $18 Million Series C Financing Led by Shepherd Kaplan Krochuk, LLC
Summary
The financing was led by the Alternative Investment division of Shepherd Kaplan Krochuk, LLC (SKK), a diversified Wealth and Asset Management firm located in Boston, Massachusetts. NanoDxTM fits SKKs investment strategy, which focuses on cutting-edge, proprietary technology platforms addressing large endemic issues and conditions in the global markets. The Company received a Breakthrough Device designation from the FDA in January 2019 for its first application as a screen to a CT scan for patients suspected of having mild traumatic brain injury. The companys NanoDxTM System is based on proprietary nanotechnology biosensors which rapidly detect and accurately measure protein biomarkers that are released from the brain immediately following a head trauma or jolt to the body or that are present in patients with an active virus. " BioDirection® is a privately held medical device company developing cutting-edge and rapid point-of-care products for the objective diagnosis and management of concussion and other traumatic brain injury (TBI).